The 2nd Annual Ottawa Heart Research Conference: Personalized Cardiovascular Medicine
Ottawa Convention Centre, Thursday, May 8, 2014

CONFERENCE PROGRAM

7:30 – 8:15 Breakfast
Colonel By Foyer

8:15 – 8:20 Welcome
Dr Ruth McPherson, Chair
Dr Katey Rayner, Vice Chair

8:20 – 8:30 Welcome Address
Dr Thierry Mesana, President and CEO
University of Ottawa Heart Institute

8:30 – 12:00 SESSION I
Genetics and Pharmacogenomics

*Learning Objectives: By the end of this session, participants will be able to:

8:30 – 9:10 Cardiovascular Pharmacogenomics: Giving the right drug to the right patient
Dr Naveen Pereira
Mayo Clinic

* Illustrate the concept of genetic variation and its effect on drug response
* Apply the currently used strategy to evaluate the effect of genetic variation on drug response
* Recall the pharmacokinetic and pharmacodynamic pathways of drug effect
* Recall the effect of genetic variation on the action of beta-blockers, Warfarin and Clopidogrel

9:10 – 9:25 Need for Speed: The power of point-of-care DNA testing
Dr Paul Lem
Spartan Bioscience Inc

* Comprehend the clinical need for rapid CYP2C19 results for PCI patients
* Identify how point-of-care genetic testing will improve patient care in the future

9:25 – 10:00 HONORARY LECTURE
Genetics of Coronary Artery Disease
Dr Robert Roberts
University of Ottawa Heart Institute

10:00 – 10:15 Break
Colonel By Foyer

JOINT PLENARY SESSION with the 4th Annual Canadian Cardiac Oncology Network Conference

10:15 – 11:10 Kinase inhibitors in cancer and the heart: Dealing with the other side of the coin
Dr Thomas Force
Temple University

* Recognize mechanisms of cardio toxicity of kinase inhibitors
* Recall future directions to prevent cardio toxicity
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 – 11:45</td>
<td>The Future of Personalized Medicine: Economics, Regulatory and Technology</td>
<td>Dr Brian O’Rourke, Canadian Agency for Drugs and Technologies in Health (CADTH)</td>
</tr>
<tr>
<td>11:45 – 12:00</td>
<td>Why Simple Collection of High Quality Samples Makes a Difference</td>
<td>Dr Chaim Birnboim, DNA Genotek Inc</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>Lunch</td>
<td>Colonel By Foyer</td>
</tr>
<tr>
<td>13:00 – 15:00</td>
<td>SESSION II: Emerging Tools for Diagnosis and Disease Management</td>
<td></td>
</tr>
<tr>
<td>13:00 – 13:40</td>
<td>Mining GWAS Data to Obtain a Better Understanding of Complex Disease</td>
<td>Dr Ruth McPherson, University of Ottawa Heart Institute</td>
</tr>
<tr>
<td>13:40 – 14:20</td>
<td>Human Pluripotent Stem Cells: From mechanisms of disease to novel therapeutics</td>
<td>Dr William Stanford, Ottawa Hospital Research Institute</td>
</tr>
<tr>
<td>14:20 – 15:00</td>
<td>Epigenetics and Cardiovascular Disease</td>
<td>Dr Philip Marsden, St Michael’s Hospital</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Break</td>
<td>Colonel By Foyer</td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>SESSION III: New Kids on the Block: Personalized Medicine in 2014</td>
<td></td>
</tr>
<tr>
<td>15:30 – 16:15</td>
<td>Restoring a Failing Heart: A dynamic effect of myocardial proteins</td>
<td>Dr Pei Pei Ping, University of California, Los Angeles (UCLA)</td>
</tr>
<tr>
<td>16:15 – 16:30</td>
<td>Closing Remarks and Evaluations</td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:00</td>
<td>Poster Session and Networking Reception</td>
<td>Rideau Canal Atrium</td>
</tr>
<tr>
<td>18:00 – 18:15</td>
<td>Closing</td>
<td>Rideau Canal Atrium</td>
</tr>
</tbody>
</table>